HTMwire
Palo Alto Networks (IoT Medical) logo

Palo Alto Networks (IoT Medical)

Device Security Platforms

HTMwire assessment

Medical IoT Security with ML-powered device discovery, MDS2 risk assessment, behavioral anomaly detection, and Zero Trust clinical device segmentation.

Key Features

  • ML-powered device discovery and classification using App-ID and deep packet inspection with three-tiered ML model
  • MDS2-informed risk assessment with CVE, SBOM mapping, and Unit 42 threat intelligence integration
  • Behavioral anomaly detection with automated security responses (e.g., bandwidth abuse isolation)
  • Context-aware network segmentation with risk-based policy recommendations to restrict lateral movement
  • Dual dashboards for IT and biomed engineering teams with AIMS and Epic Systems integration

What It Helps You Do

ML device discovery Risk-based segmentation Behavioral anomaly detection Automated response

What Sets Them Apart

Enterprise-grade Zero Trust medical device security with ML-powered discovery, MDS2-informed risk scoring, and automated threat response — backed by the scale and threat intelligence of a leading cybersecurity platform.

How Palo Alto Networks (IoT Medical) Uses AI

Uses AI/ML Machine LearningBehavioral analytics

HTMwire's independent read on the technology — not the vendor's marketing claim.

Three-tiered ML model for device identification, behavioral anomaly detection, and automated security response for medical IoT devices using network traffic analysis

  • Three-tier ML device discovery. Patented three-tier machine learning model discovers and classifies network-connected medical devices, including never-before-seen devices.
  • Behavioral anomaly detection. Detects anomalous device behavior and triggers automated responses such as isolating bandwidth-abusing devices.

Key Numbers

  • Generally available January 2023; built on Zingbox (2019, ~$75M)
  • Palo Alto Networks serves 70,000+ organizations in 150+ countries

Integrations

Epic Systems AIMS

Tags

iomt-security network-monitoring vulnerability-management

Trust Signals

Founders
Palo Alto Networks was founded in 2005 by Nir Zuk; Medical IoT Security builds on its 2019 acquisition of Zingbox, an AI/ML-based IoT security company.
Customers
70,000+ organizations in 150+ countries, including 85 of the Fortune 100
Investors / Funding
Publicly traded (NASDAQ: PANW); acquired Zingbox in 2019 for approximately $75M to build its IoT Security foundation.

Frequently Asked Questions

Does Palo Alto Medical IoT Security use machine learning to find devices?

Yes. Medical IoT Security uses machine learning, described as a three-tier ML model, to automatically discover and classify connected medical devices, including never-before-seen devices, from network traffic.

When did Palo Alto launch Medical IoT Security and what is it built on?

Palo Alto announced Medical IoT Security in late 2022 with general availability in January 2023. It extends Palo Alto's IoT Security capability, which is rooted in its 2019 acquisition of Zingbox (an AI/ML-based IoT security company) for approximately $75M.

Does Medical IoT Security integrate with biomed asset management and ITSM tools?

Yes. Palo Alto documents integration with AIMS (the Phoenix Data Systems asset management system used by many HTM teams), importing device inventory and pushing vulnerabilities as work orders, and it integrates natively with ServiceNow, Splunk, and Cortex XSOAR. We could not verify a direct Epic integration from public sources.

Is Palo Alto Networks a stable vendor for a hospital to standardize on?

Yes. Palo Alto Networks is a publicly traded cybersecurity leader (NASDAQ: PANW) serving more than 70,000 organizations across 150+ countries, giving Medical IoT Security enterprise-scale backing and threat intelligence.

Sources

  1. Palo Alto Networks announces Medical IoT Security (ML, GA Jan 2023)
  2. Palo Alto Networks completes Zingbox acquisition (~$75M)
  3. Palo Alto docs: integrate IoT Security with AIMS

We cite a primary or named source for every claim on this page. How we evaluate →

Last updated: June 9, 2026